EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in NSCLC
It is intended as monotherapy for the adjuvant treatment of adults with non-small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy